Last reviewed · How we verify

NCT05280392: AMEP-EHVA T02

Expectation, Motivation and Experience of HIV-patients Regarding Participation to an HIV Cure-related Clinical Trial

Terminated Last updated 15 May 2023
What this trial tests

trial testing Self-administered questionnaires in HIV Seropositivity in 6 participants. Terminated before completion.

Timeline
21 June 2022
Primary endpoint
30 March 2023
30 March 2023

Quick facts

Lead sponsorANRS, Emerging Infectious Diseases
StatusTerminated
Study typeOBSERVATIONAL
Enrollment6
Start date21 June 2022
Primary completion30 March 2023
Estimated completion30 March 2023
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

ANRS, Emerging Infectious Diseases — full company profile →

Who can join

Adults 18 to 65, any sex, with HIV Seropositivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Following the ANRS-APSEC survey, AMEP-EHVA T02 is a longitudinal social science study that will explore the experience of people living with HIV (PLWH) who were offered to participate in the European randomized phase II placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine including antiretroviral treatment interruption (EHVA T02/ANRS VRI07).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Self-administered questionnaires

Trials testing the same drug.

Other recruiting trials for HIV Seropositivity

Currently open trials in the same condition.

Other ANRS, Emerging Infectious Diseases trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05280392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing